Leukoreduction system chambers are a reliable cellular source for the manufacturing of T-cell therapeutics
Gabrielle Boudreau
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCédric Carli
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCaroline Lamarche
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCaroline Rulleau
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorGuillaume Bonnaure
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Medical Affairs and Innovation, Héma-Québec, Québec, Québec, Canada
Search for more papers by this authorSonia Néron
Medical Affairs and Innovation, Héma-Québec, Québec, Québec, Canada
Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Québec, Québec, Canada
Search for more papers by this authorCorresponding Author
Jean-Sébastien Delisle
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Hematology-Oncology Division, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Department of Medicine, Université de Montréal, Montreal, Québec, Canada
Address reprint requests to: Jean-Sébastien Delisle, Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, 5415 boul. de L'Assomption, Montréal, QC H1T 2M4, Canada; e-mail: [email protected]Search for more papers by this authorGabrielle Boudreau
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCédric Carli
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCaroline Lamarche
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorCaroline Rulleau
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Search for more papers by this authorGuillaume Bonnaure
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Medical Affairs and Innovation, Héma-Québec, Québec, Québec, Canada
Search for more papers by this authorSonia Néron
Medical Affairs and Innovation, Héma-Québec, Québec, Québec, Canada
Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Québec, Québec, Canada
Search for more papers by this authorCorresponding Author
Jean-Sébastien Delisle
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Hematology-Oncology Division, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
Department of Medicine, Université de Montréal, Montreal, Québec, Canada
Address reprint requests to: Jean-Sébastien Delisle, Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, 5415 boul. de L'Assomption, Montréal, QC H1T 2M4, Canada; e-mail: [email protected]Search for more papers by this authorAbstract
BACKGROUND
Following solid organ or hematopoietic cell transplantation, refractory opportunistic viral reactivations are a significant cause of morbidity and mortality but can effectively be controlled by virus-specific T-cell transfer. Among effective and safe strategies is the use of “third-party” (neither from the transplant donor nor recipient) virus-specific T cells that can be manufactured from healthy donors and used as “off-the-shelf” therapies. Leukoreduction system chambers (LRSCs), recovered after routine plateletpheresis, were evaluated as a potential source of peripheral blood mononuclear cells (PBMCs) for the manufacturing of clinical-scale virus-specific T cell.
STUDY DESIGN AND METHODS
PBMCs from the same donors obtained either from LRSCs or peripheral blood were compared, focusing on T-cell function and phenotype as well as the potential to generate cytomegalovirus (CMV)-specific T-cell lines from both CMV seropositive and seronegative donors.
RESULTS
PBMCs from both sources were comparable except for a transient downregulation of CD62L expression on freshly extracted PBMCs from LRSCs. Both nonspecific stimulation using anti-CD3/CD28 antibodies and CMV peptides revealed that LRSCs or blood T cells were equivalent in terms of expansion, differentiation, and function. Moreover, PBMCs from LRSCs can be used to generate autologous monocyte-derived dendritic cells to prime and expand CMV-specific T cells from seronegative donors.
CONCLUSION
LRSCs are a reliable source of PBMCs for the generation of virus-specific T cells for immunotherapy. These findings have implications for the development of third-party therapeutic T-cell products from well-characterized blood product donors.
CONFLICT OF INTEREST
The authors have disclosed no conflicts of interest.
REFERENCES
- 1Shapiro MJ. To filter blood or universal leukoreduction: what is the answer? Crit Care 2004; 8(Suppl 2): S27-30.
- 2Knorck A, Marx S, Friedmann KS, et al. Quantity, quality, and functionality of peripheral blood cells derived from residual blood of different apheresis kits. Transfusion 2018; 58: 1516-26.
- 3Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941-9.
- 4Bassuni WY, Blajchman MA, Al-Moshary MA. Why implement universal leukoreduction? Hematol Oncol Stem Cell Ther 2008; 1: 106-23.
- 5Dietz AB, Bulur PA, Emery RL, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 2006; 46: 2083-9.
- 6Neron S, Thibault L, Dussault N, et al. Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells. Transfusion 2007; 47: 1042-9.
- 7Lemieux J, Jobin C, Simard C, et al. A global look into human T cell subsets before and after cryopreservation using multiparametric flow cytometry and two-dimensional visualization analysis. J Immunol Methods 2016; 434: 73-82.
- 8Pfeiffer IA, Zinser E, Strasser E, et al. Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes. Immunobiology 2013; 218: 1392-401.
- 9Nordgren IK. Leukoreduction system chambers provide a valuable source of functional monocytes for the monocyte activation test by comparison with internationally validated methods. J Immunol Methods 2016; 428: 42-9.
- 10Peytour Y, Villacreces A, Chevaleyre J, et al. Discarded leukoreduction filters: a new source of stem cells for research, cell engineering and therapy? Stem Cell Res 2013; 11: 736-42.
- 11Rooney CM, Leen AM, Vera JF, et al. T lymphocytes targeting native receptors. Immunol Rev 2014; 257: 39-55.
- 12Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev 2014; 257: 250-63.
- 13Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65: 333-47.
- 14Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017; 545: 423-31.
- 15Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-31.
- 16Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045-9.
- 17Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121: 5113-23.
- 18Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2017; 35: 3547-57.
- 19Linden PK. History of solid organ transplantation and organ donation. Crit Care Clin 2009; 25: 165-84 ix.
- 20Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol 2010; 125(2 Suppl 2): S324-35.
- 21de la Morena MT, Gatti RA. A history of bone marrow transplantation. Immunol Allergy Clin North Am 2010; 30: 1-15.
- 22Lamarche C, Orio J, Collette S, et al. BK polyomavirus and the transplanted kidney: immunopathology and therapeutic approaches. Transplantation 2016; 100: 2276-87.
- 23Breuer S, Rauch M, Matthes-Martin S, et al. Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther 2012; 16: 63-77.
- 24Aguilar C, Husain S, Lortholary O. Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Res 2018;7 (F1000 Faculty Rev), 661: 1–9.
- 25Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 2016; 127: 3331-40.
- 26Withers B, Blyth E, Clancy LE, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv 2017; 1: 2193-205.
- 27Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-35.
- 28Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9: 510-9.
- 29Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-9.
- 30Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
- 31Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592-8.
- 32Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12: 671-84.
- 33Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev 2014; 257: 264-76.
- 34Robillard P, Delage G, Itaj NK, et al. Use of hemovigilance data to evaluate the effectiveness of diversion and bacterial detection. Transfusion 2011; 51: 1405-11.
- 35Bonnaure G, Gervais-St-Amour C, Neron S. Bone marrow mesenchymal stem cells enhance the differentiation of human switched memory B lymphocytes into plasma cells in serum-free medium. J Immunol Res 2016; 2016: 7801781.
- 36Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral Infections. Mol Ther 2012; 20: 1622-32.
- 37Orio J, Carli C, Janelle V, et al. Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation. Cytotherapy 2015; 17: 496-508.
- 38Janelle V, Carli C, Taillefer J, et al. Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. J Transl Med 2015; 13: 123.
- 39Lamarche C, Orio J, Georges-Tobar V, et al. Clinical-scale rapid autologous BK virus-specific T cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy. Transplantation 2017; 101: 2713-21.
- 40Thibault L, Beausejour A, Jacques A, et al. Overnight storage of whole blood: cooling and transporting blood at room temperature under extreme temperature conditions. Vox Sang 2014; 106: 127-36.
- 41Zhao L, Shey M, Farnsworth M, et al. Regulation of membrane metalloproteolytic cleavage of L-selectin (CD62l) by the epidermal growth factor domain. J Biol Chem 2001; 276: 30631-40.
- 42Zamora MR. DNA viruses (CMV, EBV, and the herpesviruses). Semin Respir Crit Care Med 2011; 32: 454-70.
- 43Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 2016; 127: 2427-38.
- 44Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6: 242ra283.
- 45Neron S, Dussault N, Racine C. Whole-blood leukoreduction filters are a source for cryopreserved cells for phenotypic and functional investigations on peripheral blood lymphocytes. Transfusion 2006; 46: 537-44.
- 46Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol 2002; 168: 909-18.
- 47Comoli P, Ginevri F, Maccario R, et al. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am J Transplant 2006; 6: 2169-76.
- 48Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114: 1958-67.
- 49Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med 2015; 7: 285ra263.
- 50Isasi R, Mastronardi C, Golder M, et al. Assessing opportunities and challenges for establishing a national program to distribute cord blood for research. Transfusion 2018; 58: 1726-31.
Citing Literature
